Fragmin · DIN 02352656 · 10000IU/0.4mL · injection, pre-filled syringe
Limited Use — Reason for Use code 186, 187, 188, 189 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 186, 187, 188, 189 required
Write on scriptLU code 186, 187, 188, 189 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria — code 186, 187, 188, 189
Reason for Use code 186
For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 187
For DVT in pregnant or lactating females;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 188
For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 189
For DVT in patients who have failed treatment with warfarin.
Coverage limit:
LU Authorization Period: 1 year
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dalteparin
Brand(s): Fragmin
DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products
For peri-operative bridging for patients who require long-term warfarin therapy and must
temporarily discontinue it before and after surgery, and who are at moderate- to high-risk
for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the date
of surgery plus up to 7 days after surgery.
For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on the
day of surgery.
For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or risk
factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days
For extended treatment of symptomatic acute venous thromboembolism (VTE) in
patients with cancer for whom warfarin treatment is not appropriate on a case-by-case
basis.
Standard Approval Duration: 6 months
28
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 28, record 7, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Dalteparin
Brand(s): Fragmin
DOSAGE FORM/ STRENGTH: Check e-formulary for funded strengths
1. For peri-operative bridging for patients who require long-term warfarin therapy and
must temporarily discontinue it before and after surgery, and who are at moderate- to
high-risk for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the
date of surgery plus up to 7 days after the date of hospital discharge
2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on
the day of surgery
3. For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or
risk factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days.
4. For extended treatment of symptomatic acute venous thromboembolism (VTE)
in patients with cancer, who cannot use warfarin.
Standard Approval Duration: As requested up to 6 months
469
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 469, record 308, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)
No interchangeable product listed in the Ontario extract
Fragmin · DIN 02352656
Manufacturer: Pfizer Canada Inc.; listing date 2011-03-15
Health Canada: Marketed since 2011-02-01 · brand FRAGMIN · ATC B01AB04 DALTEPARIN · form Solution · route Intravenous, Subcutaneous · ingredients DALTEPARIN SODIUM 10000 UNIT/0.4ML · company Pfizer canada ulc · schedule Prescription
Fragmin: Formulary list price $24.2012/unit (unit not stated in source; not the patient's cost)
Ministry pays: $24.2012 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83791 · Verify on the e-Formulary ↗ (DIN 02352656)
Source record
DIN 02352656: Fragmin
Raw flags: sec12=Y, sec3=Y
Item: 201200064; group id 253; item number 0452; lccId 00045; manufacturer id PFI
Source form: Inj Pref Syr; strength: 10000IU/0.4mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $24.2012; ministry $24.2012
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02352656
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83791
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02352656
Shortage record checked 2026-09-13T08:10:21.292534+00:00